We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 258

Judge finds biosimilar patent procedures optional

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 23 2015

Judge Seeborg of the U.S. District Court for the Northern District of California issued an order inAmgen, Inc. v. Sandoz, Inc., ruling that the

USPTO issues final Patent Term Adjustment rules under Novartis

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • January 12 2015

The USPTO has published final Patent Term Adjustment (PTA) rules addressing the treatment of Requests for Continued Examination (RCEs) under the

District court invalidates USPTO interpretation of patent term adjustment RCE carve-out

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • November 5 2012

In a decision issued November 1, 2012 in Exelixis, Inc. v. Kappos, the U.S. District Court for the Eastern District of Virginia has found that the USPTO’s interpretation and application of the “RCE carve-out” provision of the Patent Term Adjustment (PTA) statute is contrary to law

The Remicade biosimilar patent dispute

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 10 2015

While Sandoz has grabbed the biosimilar headlines for being the first company to have a product approved under the Biologics Price Competition and

Fresenius escapes $25 million damages award, based on invalidation of Baxter Patent in ex parte reexamination

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • July 8 2013

In Fresenius, USA Inc. v. Baxter International, Inc., the Federal Circuit interpreted the ex parte reexamination statutes (35 USC §

Federal Circuit finds no written description support for Novozymes amylase patent

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • July 25 2013

In Novozymes AS v. DuPont Nutrition Biosciences APS, the Federal Circuit determined that the Novozymes amylase patent at issue did not satisfy the

Federal Circuit finds Yaz patent obvious

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 25 2013

In Bayer Healthcare Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc., the Federal Circuit reversed the district court and held that Bayer's

Federal Circuit upholds Patent Term Adjustment deduction for IDS filed after Restriction Requirement

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 2 2015

In Gilead Sciences, Inc. v. Lee, the Federal Circuit upheld the USPTO's interpretation of the Patent Term Adjustment (PTA) statute as permitting the

Patent term adjustment - challenging applicant delays

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 22 2011

Hoffman-La Roche Inc. and Morphosys AG are among the latest patent holders to file a Patent Term Adjustment (PTA) action against the USPTO

Federal Circuit takes a close look at patent assignment language

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 23 2011

In MHL Tek, LLC v. Nissan Motor Co., the Federal Circuit took a careful look at patent assignment language and determined that an earlier assignment encompassed all asserted patents, and so the later assignment to the plaintiff was ineffective, leaving the plaintiff with no standing